Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 12, 2003 - Issue 2
Submit an article Journal homepage
285
Views
45
CrossRef citations to date
0
Altmetric
Review

Novel agents and strategies to treat herpes simplex virus infections

Gerald Kleymann Leopoldshöherstraße 7, D-32107 Bad-Salzuflen, Germany. [email protected]
Pages 165-183 | Published online: 02 Mar 2005

Bibliography

  • Fields Virology (4th Edn). DM Knipe, PM Howley (Eds), Lippincott Williams & Wilkins, Philadelphia, US (2001).
  • •The reference book.
  • BREN L: Genital herpes: a hidden epidemic. FDA Consum. (2002) 36(2):10–16.
  • SMITH JS, ROBINSON NJ: Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J. Infect. Dis. (2002) 186\(Suppl. 1):53–528.
  • USTACELEBI S: Diagnosis of herpes simplex virus infections. J. Clin. Viral. (2001) 21(3):255–259.
  • ASHLEY RL: Performance and use of HSV type-specific serology test kits. Hopes (2002) 9(2):38–45.
  • CASPER C, WALD A: Condom use and the prevention of genital herpes acquisition. Herpes (2002) 9(1):10–14.
  • ZEITLIN L, WHALEY KJ: Microbicides for preventing transmission of genital herpes. Herpes (2002) 9(1):4–9.
  • •A thorough review of microbicides.
  • STANBERRY LR, CUNNINGHAM AL, MINDEL A et al.: Prospects for control of herpes simplex virus disease through immunization. Clin. Infect. Dis. (2000) 30(3):549–566.
  • •Discussing the objectives of vaccines against herpes.
  • WHITLEY RJ, ROIZMAN B: Herpes simplex viruses: is a vaccine tenable?J. Clin. Invest. (2002) 110(2):145–151.
  • VANDEPAPELIERE P: Therapeutic vaccination against chronic viral infections. Lancet Infect. Dis. (2002) 2(6):353–367.
  • MORRISON LA: Vaccines against genital herpes: progress and limitations. Drugs (2002) 62(8):1119–1129.
  • STANBERRY LR, VANDEPAPELIERE P: Herpes simplex virus vaccines. In: Genital Herpes. A Volpi (Ed.), Ii Pensiero Scientifico Editore, Rome (In Press).
  • WHITLEY RJ: Herpes simplex vaccines. In: New Generation Vaccines. MM Levine, JB Kaper, R Rappuoli, M Liu, M Good (Eds), Marcel Dekker, Inc. New York, USA (2002) (In press).
  • COREY L, LANGENBERG AG, ASHLEY R et al.: Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA (1999) 282(4):331–340.
  • STANBERRY LR, SPRUANCE SL, CUNNINGHAM AL et al.: Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N EngL J. Med. (2002) 347(21):1652–1661.
  • EO SK, PACK C, KUMARAGURU U, ROUSE BT: Optimisation of DNA vaccines for the prophylaxis and modulation of herpes simplex virus infections. Expert Opin. Biol. Ther. (2001) 1(2):213–225.
  • GERSHON AA: Live-attenuated varicella vaccine. Infect. Dis. Clin. North Am. (2001) 15(1):65–81.
  • CUNNINGHAM AL, MIKLOSKA Z: The Holy Grail: immune control of human herpes simplex virus infection and disease. Herpes (2001) 8\(Suppl. 1):6A–10A.
  • FAVOREEL HW, NAUWYNCK HJ, PENSAERT MB: Immunological hiding of herpesvirus-infected cells. Arch. Viral. (2000) 145(7):1269–1290.
  • BECKER Y: Herpes simplex virus evolved to use the human defense mechanisms to establish a lifelong infection in neurons-a review and hypothesis. Virus Genes (2002) 24(2):187–196.
  • BERNSTEIN DI: Potential for immunotherapy in the treatment of herpesvirus infections. Hopes (2001) 8(1):8–11.
  • DOCKRELL DH, KINGHORN GR: Imiquimod and resiquimod as novel immunomodulators. j Antimicrob. Chemother. (2001) 48(6):751–755.
  • STANLEY MA: Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. DermataL (2002) 27(7):571–577.
  • JURK M, HEIL F, VOLLMER J et cll.: Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol (2002) 3(6):499.
  • HEMMI H, KAISHO T, TAKEUCHI 0 et al.: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. ImmunoL (2002) 3(2):196–200.
  • SPRUANCE SL, TYRING SK, SMITH MH, MENG TC: Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J. Infect. Dis. (2001) 184(2):196–200.
  • DE MARIA A, TUNDO P, ROMANO A et al.: Anti-HSV-1 herpes vaccination by Lupidon H: preliminary results. Adv. Exp. Med. Biol. (1995) 371B:1599–1600.
  • CARR JA, ROGERSON J, MULQUEEN MJ, ROBERTS NA, BOOTH RF: Interleukin-12 exhibits potent antiviral activity in experimental herpesvirus infections. J. Viral (1997) 71(10):7799–7803.
  • VOLLSTEDT S, FRANCHINI M, ALBER G, ACKERMANN M, SUTER M: Interleukin-12- and gamma interferon-dependent innate immunity are essential and sufficient for long-term survival of passively immunized mice infected with herpes simplex virus Type 1.j Viral. (2001) 75(20):9596–9600.
  • HARANDI AM, SVENNERHOLM B, HOLMGREN J, ERIKSSON K: Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus Type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity. J. Viral. (2001) 75(14):6705–6709.
  • AL-KHATIB K, CAMPBELL IL, CARR DJ: Resistance to ocular herpes simplex virus Type 1 infection in IL-12 transgenic mice. J. NeuraimmunaL (2002) 132(1-2):41–48.
  • NOISAKRAN S, CARR DJ: Type I interferons and herpes simplex virus infection: a naked DNA approach as a therapeutic option? ImmunaL Res. (2001) 24(1):1–11.
  • KAUFMAN HE: Clinical cure of herpes simplex keratitis by 5-iodo-2'-deoxyuridine. Proc. Soc. Exp. Biol. Med. (1962) 109:251–252.
  • KAUFMAN HE, HEIDELBERGER C: Therapeutic antiviral action of 5-trifluoromethy1-2'-deoxyuridine. Science (1964) 145:585–586.
  • ELTON GB, FURMAN PA, FYFE JA, DE MIRANDA P, BEAUCHAMP L, SCHAEFFER HJ: The selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Reproduced from Proc. Natl Acad. Sci. USA (1977) 74:5716-5720. Rev. Med. Viral. (1999) 9(3):147–152; Discussion 152–153.
  • SCHAEFFER HJ, BEAUCHAMP L, DE MIRANDA P, ELTON GB, BAUER DJ, COLLINS P: 9-(2-hydroxyethoxyrnethyl) guanine activity against viruses of the herpes group. Nature (1978) 272(5654):583–585.
  • •• Landmark paper of antiviral research.
  • O'BRIEN JJ, CAMPOLI-RICHARDS DM: Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1989) 37(3):233–309.
  • WHITLEY RJ, GNANN JW Jr: Acyclovir: a decade later. N Engl. J Med. (1992) 327(11):782–789. Erratum in: N EngL Med. (1993) 328(9):671. N EngL J Med. (1997) 337(23):1703.
  • BEUTNER KR: Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res. (1995) 28(4):281–290.
  • PERRY CM, FAULDS D: Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs (1996) 52(5):754–772.
  • BELL AR: Valaciclovir update. Adv. Exp. Med. Biol. (1999) 458:149–157.
  • JARVEST RL, SUTTON D, VERE HODGE RA: Famciclovir. Discovery and development of a novel antiherpesvirus agent. Pharm. BiotechnoL (1998) 11:313–343.
  • NAESENS L, DE CLERCQE: Recent developments in herpesvirus therapy. Herpes (2001) 8(1):12–16.
  • VILLARREAL EC: Current and potential therapies for the treatment of herpesvirus infections. Prog. Drug Res. (2001) 56:77-120 and Spec No:185-228.
  • ABDEL-HAQ NM, ASMAR BI: Anti-herpes viruses agents. Indian J. Pediatr. (2001) 68(7):649–654.
  • WHITLEY RJ, ROIZMAN B: Herpes simplex virus infections. Lancet (2001) 357(9267): 1513–1518.
  • •An up-to-date review of herpes therapy.
  • SNOECK R: Antiviral therapy of herpes simplex. Int. J Antimicrob. Agents (2000) 16(2):157–159.
  • SNOECK R, DE CLERCQ E: New treatments for genital herpes. Curr. Opin. Infect. Dis. (2002) 15(1):49–55.
  • WATHEN MW: Non-nucleoside inhibitors of herpesviruses. Rev. Med. ViroL (2002) 12(3):167–178.
  • YEUNG-YUE KA, BRENTJENS MH, LEE PC, TYRING SK: The management of herpes simplex virus infections. Curr. Opin. Infect. Dis. (2002) 15(2):115–122.
  • STANBERRY L, CUNNINGHAM A, MERTZ Get aL: New developments in the epidemiology, natural history and management of genital herpes. Antiviral Res. (1999) 42(1):1–14.
  • KEATING MR: Antiviral agents for non-human immunodeficiency virus infections. Mayo Clin. Proc. (1999) 74(12):1266–1283.
  • ROIZMAN B, WHITLEY RJ: The nine ages of herpes simplex virus. Hypes (2001) 8(1):23–27.
  • DE CLERCQ E, ANDREI G, SNOECK R et al.: Acyclic/carbocyclic guanosine analogues as anti-herpesvirus agents. Nucleosides Nucleotides Nucleic Acids (2001) 20(4-7):271–285.
  • GORDON YJ: The evolution of antiviral therapy for external ocular viral infections over twenty-five years. Cornea (2000) 19(5):673–680.
  • KAUFMAN HE: Treatment of viral diseases of the cornea and external eye. Prog. Retin. Eye Res. (2000) 19(1):69–85.
  • BARNARD DL: Genvir (Flamel Technologies). Curr. Opin. Investig. Drugs (2001) 2(5):622–623.
  • ALBIN R, CHASER, RISANO C et aL: SCH 43478 and analogs: in vitro activity and in vivo efficacy of novel agents for herpesvirus Type 2. Antiviral Res. (1997) 35(3):139–146.
  • FIELD HJ: Herpes simplex virus antiviral drug resistance-current trends and future prospects. J Clin. ViroL (2001) 21(3):261–269.
  • COLLINS P: Mechanisms of herpes virus resistance. Ann. Med. (1993) 25(5):441–445.
  • COLLINS P, DARBY G: Laboratory studies of herpes simplex virus strains resistant to acyclovir. Rev. Med. ViroL (1991) 1:19–28.
  • COEN DM: Acyclovir-resistant, pathogenic herpesviruses. Trends MicrobioL (1994) 2:481–485.
  • GILBERT C, BESTMAN-SMITH J, BOIVIN G: Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Updates (2002) 5(2):88–114.
  • WAXMAN L, DARKE PL: The herpesvirus proteases as targets for antiviral chemotherapy. Antivir. Chem. Chemother. (2000) 11(1):1–22.
  • •Comprehensive review on herpes proteases.
  • JARVEST RL, PINTO IL, ASHMAN SM et al.: Inhibition of herpes proteases and antiviral activity of 2-substituted thieno [2,3-d]oxazinones. Bioorg. Med. Chem. Lett. (1999) 9(3):443–448.
  • MATSUMOTO M, MISAWA S, CHIBA N, TAKAKU H, HAYASHI H: Selective nonpeptidic inhibitors of herpes simplex virus Type 1 and human cytomegalovirus proteases. Biol. Pharm. Bull. (2001) 24(3):236–241.
  • AOKI H, AKAIKE T, ABE K et al.: Antiviral effect of oryzacystatin, a proteinase inhibitor in rice, against herpes simplex virusType 1 in vitro and in vivo. Antimicrob. Agents Chemother. (1995) 39(0846–849.
  • BJORCK L, GRUBB A, KJELLEN L: Cystatin C, a human proteinase inhibitor, blocks replication of herpes simplex virus. J ViroL (1990) 64(2):941–943.
  • OIEN NL, BRIDEAU RJ, HOPKINS TA et al.: Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors. Antimicrob. Agents Chemother. (2002) 46(3):724–730.
  • •A novel compound class with broad-spectrum activity.
  • BRIDEAU RJ, KNECHTEL ML, HUANG A et al.: Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses. Antiviral Res. (2002) 54(1):19–28.
  • KUROKAWA M, HOZUMI T, TSURITA M, KADOTA S, NAMBA T, SHIRAKI K: Biological characterization of eugeniin as an anti-herpes simplex virusType 1 compound in vitro and in vivo. J. PharmacoL Exp. Then (2001) 297(1):372–379.
  • LIUZZI M, DEZIEL R, MOSS Net al.: A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature (1994) 372(6507):695–698.
  • MOSS N, BEAULIEU P, DUCEPPE JS et al.: Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase: a new class of antiviral agents. J Med. Chem. (1995) 38(18):3617–3623.
  • DUAN J, LIUZZI M, PARIS Wet al.: Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus Type 1 in vivo. Antimicrob. Agents Chemother. (1998) 42(7):1629–1635.
  • BRIDGES CG, AHMED SP, SUNKARA PS, MCCARTHY JR, TYMS AS: The ribonucleotide reductase inhibitor (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731): a potential topical therapy for herpes simplex virus infection. Antiviral Res. (1995) 27(4):325–334.
  • SAFRIN S, SCHACKER T, DELEHANTY J, HILL E, COREY L: Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir. Antimicrob. Agents Chemother. (1993) 37(5):975–979.
  • SAFRIN S, SCHACKER T, DELEHANTY J, HILL E, COREY L: Potential for combined therapy with 348U87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection. J. Med. ViroL (1993) Suppl. 1:146–149.
  • SPECTOR T, HARRINGTON JA, PORTER DJ: Herpes and human ribonucleotide reductases. Inhibition by 2-acetylpyridine 5-[(2-chloroanilino)-thiocarbony1]-thiocarbonohydrazone (348U87). Biochem. PharmacoL (1991) 42(1):91–96.
  • SPECTOR T, HARRINGTON JA, MORRISON RW et aL: 2-Acetylpyridine 5-[(dimethylarnino)thiocarbony1]-thiocarbonohydrazone (A11 10U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir. Proc. Nail. Acad. Sci. USA (1989) 86(3):1051–1055.
  • TURK SR, SHIPMAN C Jr, DRACH JC: Selective inhibition of herpes simplex virus ribonucleoside diphosphate reductase by derivatives of 2-acetylpyridine thiosemicarbazone. Biochem. PharmacoL (1986) 35(9):1539–1545.
  • CARADONNA SJ, CHENG YC: Inductionof uracil-DNA glycosylase and dUTP nucleotidohydrolase activity in herpes simplex virus-infected human cells. J. Biol. Chem. (1981) 256(19):9834–9837.
  • FOCHER F, VERRI A, SPADARI S, MANSERVIGI R, GAMBINO J, WRIGHT GE: Herpes simplex virusType 1 uracil-DNA glycosylase: isolation and selective inhibition by novel uracil derivatives. Biochem. J. (1993) 292(Pt 3):883–889.
  • PYLES RB, THOMPSON RL: Evidence that the herpes simplex virus Type 1 uracil DNA glycosylase is required for efficient viral replication and latency in the murine nervous system. J. ViroL (1994) 68(8):4963–4972.
  • SAVVA R, MCAULEY-HECHT K, BROWN T, PEARL L: The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature (1995) 373 (6514):487–493.
  • SUN H, ZHI C, WRIGHT GE et aL: Molecular modeling and synthesis of inhibitors of herpes simplex virus Type 1 uracil-DNA glycosylase. J Med. Chem. (1999) 42(13):2344–2350.
  • CHEN R, WANG H, MANSKY LM: Roles of uracil-DNA glycosylase and dUTPase in virus replication. J Gen. ViroL (2002) 83(Pt 10):2339–2345.
  • WATKINS AM, DUNFORD PJ, MOFFATT AM et aL: Inhibition of virus-encoded thymidine kinase suppresses herpes simplex virus replication in vitro and in vivo. Anti vir. Chem. Chemother. (1998) 9(1):9–18.
  • MARTIN JA, THOMAS GJ, MERRETT JH et aL: The design, synthesis and properties of highly potent and selective inhibitors of herpes simplex virus types 1 and 2 thymidine kinase. Antivir. Chem. Chemother. (1998) 9(1):1–8.
  • MARTIN JA, LAMBERT RW, MERRETT JH et aL: Nucleoside analogues as highly potent and selective inhibitors of herpes simplex virus thymidine kinase. Bioorg. Med. Chem. Lett. (2001) 11(13):1655–1658.
  • GAUDIO AC, TAKAHATAY, RICHARDS WG: Prediction of the binding mode of N2-phenylguanine derivative inhibitors to herpes simplex virus Type 1 thymidine kinase. Comput. Aided MoL Des. (1998) 12(1):15–25.
  • XU H, MAGA G, FOCHER F et aL: Synthesis, properties, and pharmacolcinetic studies of N2-phenylguanine derivatives as inhibitors of herpes simplex virus thymidine kinases. J. Med. Chem. (1995) 38(1):49–57.
  • KLEYMANN G, FISCHER R, BETZ UA et al.: New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat. Med. (2002) 8(4):392–398.
  • •First tolerable compound class 25 years after the discovery of acyclovir that outperforms the gold standard with respect to all parameters of efficacy in animal models.
  • CRUMPACKER CS, SCHAFFER PA: New anti-HSV therapeutics target the helicase-primase complex. Nat. Med. (2002) 8(4):327–328.
  • •News and views article on HSV helicase-primase inhibitors.
  • BETZ UA, FISCHER R, KLEYMANN G, HENDRIX M, RUB SAMEN-WAIGMANNH: Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob. Agents Chemother. (2002) 46(6):1766–1772.
  • SPECTOR FC, LIANG L, GIORDANO H, SIVARAJA M, PETERSON MG: Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. J. ViroL (1998) 72(9):6979–6987.
  • CRUTE JJ, GRYGON CA, HARGRAVE KD et al.: Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat. Med. (2002) 8(4):386–391.
  • •Discovery of lead compounds and characterisation of the HSV helicase-primase enzyme complex.
  • SCHANG LM, BANTLY A, KNOCKAERT M et al.: Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus Type 1 by targeting cellular, not viral, proteins. J ViroL (2002) 76(15):7874–7882.
  • EBY GA, HALCOMB WW: Use of topical zinc to prevent recurrent herpes simplex infection: review of literature and suggested protocols. Med. Hypotheses (1985) 17(2):157–165.
  • FRANCKE B, MARGOLIN J: Effect of novobiocin and other DNA gyrase inhibitors on virus replication and DNA synthesis in herpes simplex virus Type 1-infected BHK cells. J. Gen. ViroL (1981) 52(Pt 2):401–404.
  • IKEDA S, YAZAWA M, NISHIMURA C: Antiviral activity and inhibition of topoisomerase by ofloxacin, a new quinolone derivative. Antiviral Res. (1987) 8(3):103–113.
  • WENTLAND MP, PERNI RB, DORFF PH et al.: Antiviral properties of 3-quinolinecarboxamides: a series of novel non-nucleoside antiherpetic agents. Drug Des. Discov. (1997) 15(1):25–38.
  • WENTLAND MP, CARLSON JA, DORFF PH et al.: Cyclic variations of 3-quinolinecarboxamides and effects on antiherpetic activity. J Med. Chem. (1995) 38(14):2541–2545.
  • WENTLAND MP, PERNI RB, DORFF PH et al.: 3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents. J Med. Chem. (1993) 36(11):1580–1596.
  • AKANITAPICHAT P, LOWDEN CT, BASTOW KF: 1,3-Dihydroxyacridone derivatives as inhibitors of herpes virus replication. Antiviral Res. (2000) 45(2):123–134.
  • EBERT SN, SHTROM SS, MULLER MT: Topoisomerase II cleavage of herpes simplex virus Type 1 DNA in vivo is replication dependent. J. Viral. (1990) 64(9):4059–4066.
  • YAMADA Y, YAMAMOTO N, MAENO K, NISHIYAMA Y: Role of DNA topoisomerase Tin the replication of herpes simplex virusType 2. Arch. Viral. (1990) 110(1-2):121–127.
  • PESSINA A, MINEO E, GRIBALDO L, NERI MG: Lack of in vitro antiviral activity of fluoroquinolones against herpes simplex virus Type 2. Arch. Viral. (1992) 122(3-4):263–269.
  • NOZAWA N, DAIKOKU T, YAMAUCHI Yet al.: Identification and characterization of the UL7 gene product of herpes simplex virus Type 2. Virus Genes (2002) 24(3):257–266.
  • KLEYMANN G: Helicase-primase inhibitors. Drugs Future (2003).
  • SAWTELL NM, POON DK, TANSKY CS, THOMPSON RL: The latent herpes simplex virus Type 1 genome copy number in individual neurons is virus strain specific and correlates with reactivation. J Viral. (1998) 72(7):5343–5350.

Websites

  • http://www.ebi.ac.uk EUROPEAN BIOINFORMATICS INSTITUTE homepage: Accession No. X14112 (HSV-1) and Z86099 (HSV–2)
  • www.microbicide.org ALLIANCE FOR MICROBICIDE DEVELOPMENT homepage.
  • www.pdr.net THOMSON HEALTHCARE Drug database.
  • www.rote-liste.de Drug database.
  • http://www.ncbi.nlm.nih.gov NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION
  • http://www.nobel.se NOBEL e-MUSEUM HOMEPAGE

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.